By excluding studies which allow the use of therapies known to increase risk (ie, SU, insulin), we have aimed to improve the estimation of hypoglycaemia risk with newer AHA when used alone or in combination with each other compared to placebo. This evidence concerns the gene INS and Hypoglycemia.